Ozempic and Vision Loss: What the FDA’s New NAION Warning Means in Illinois
Announcement from a bar association
Headline as published by Illinois Lawyer Now (ISBA) on Nov 16, 2026; collected by the wire Nov 16, 2026, 1:16 PM ET.
On November 9, 2026, the FDA ordered every company that sells a GLP-1 drug to add a new warning to its label: a possible increased risk of NAION, a rare eye condition that can cause sudden and sometimes permanent vision loss. The order covers Ozempic, Wegovy, Mounjaro, Zepbound and every other GLP-1 on the market.... Continue Reading
Coverage
Named in this story
- AgencyU.S. Food and Drug AdministrationMatched on
FDA
- MDLMDL 3163 · GLP-1 Vision Loss (NAION)Matched on
NAION
Topics
- Mass torts and MDLsMatched on
NAION
Explore the named firms, organizations and MDL dockets above. Sources and method
MDL No. 3163
GLP-1 Vision Loss (NAION)
IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation
- Transferee judge
- Karen S. Marston
- Court
- Eastern District of Pennsylvania
- Actions pending
- 247
Per the JPML pending-dockets report of October 1, 2026.